SEC Comment Letter for GT Biopharma, Inc. (GTBP) (CIK 0000109657) (GTBP) — Jul 2, 2019
GT Biopharma, Inc. (GTBP) (CIK 0000109657)
Date: July 2, 2019 · CIK: 0000109657 · Accession: 0000000000-19-010589
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-232261
Letter
July 1, 2019 Anthony J. Cataldo Chief Executive Officer GT Biopharma, Inc. 310 N. Westlake Blvd, Suite 206 Westlake Village, CA 91362 Re:GT Biopharma, Inc. Registration Statement on Form S-1 Filed June 21, 2019 File No. 333-232261 Dear Mr. Cataldo: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joseph McCann at (202) 551-6262 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
July 1, 2019
Anthony J. Cataldo
Chief Executive Officer
GT Biopharma, Inc.
310 N. Westlake Blvd, Suite 206
Westlake Village, CA 91362
Re:GT Biopharma, Inc.
Registration Statement on Form S-1
Filed June 21, 2019
File No. 333-232261
Dear Mr. Cataldo:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joseph McCann at (202) 551-6262 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance